Add to watchlist:

Only registered members can add into watchlist !

Register here !
Inovio Pharmaceuticals
Deal Inovio Pharmaceuticals Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

Inovio Pharmaceuticals, Inc. is focused on the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent or treat cancers and chronic infectious diseases. This next generation of immunotherapies could potentially protect millions of people from debilitation or death from diseases ...

Read more

Inovio announces positive animal response in SynCon anti-HPV study

Inovio Pharmaceuticals (AMEX:INO) said Monday its SynCon vaccine induced a positive T-Cell immune response in mice with diseases caused by the human papillomavirus (HPV) types 6 and 11, broadening the company's reach with the synthetic vaccine.

Inovio's SynCon technology allows it to design synthetic vaccines with the potential to protect against unmatched sub-types and strains of pathogens, including newly emergent, unknown strains of a virus that will periodically emerge through mutation, as in the case of the HPV virus.

The vaccine for these two types joins the company's existing vaccines for types 16 and 18, which is currently in a phase two clinical study.

The results were published in Human Vaccines & Immunotherapeutic, a peer-reviewed paper, titled "Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen".

Inovio president and CEO, Dr. J. Joseph Kim said: "Over a dozen HPV types are recognized as causing cancers and other diseases, with a significant health need and business opportunity for therapeutic vaccines to address these conditions.

"With the best-in-class T-cell responses generated by VGX-3100 in early human studies, our goal is to create a family of therapeutic vaccines targeting most significant diseases caused by HPV infection, including cervical cancer and dysplasia, vulvar dysplasia, head and neck cancer, and other cancers.

"This study demonstrates our ability to readily extend our therapeutic solutions to diseases caused by different HPV types.

"Importantly, our clinical experience with VGX-3100 may also help streamline the regulatory path for these related vaccines."

The new SynCon vaccines were developed to target antigens E6 and E7 of HPV 6 and HPV 11. The vaccines were then modified to increase gene expression and production of the antigenic protein.

The product was administered using the company's proprietary electroporation delivery system, which has proven to boost immune responses by up to 100-fold.

The HPV virus is the potentially deadly virus behind such diseases as head and neck cancers, and genital warts, among others.

Types 6 and 11 in particular are the major cause of recurrent respiratory papillomatosis, which is commonly manifested in warts in the airway, as well as genital warts. The strains are also associated with ear, nose and throat malignancies, carcinoma of the lung, tonsil and larynx, and low-grade cervical lesions.

In addition to the treatment of HPV, Inovio's SynCon vaccines are also undergoing clinical evaluations to treat the influenza virus, cervical dysplasia, leukemia, the hepatitis C virus, and HIV.

On the AMEX, Inovio shares spiked 8.28 percent in premarket trading, to $0.667 per share as of 8:12 am EDT.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.